Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ZSNeo-DC1.1 in Recurrent or Progressive High-grade Glioma
NCT06253234Phase 1Active, not recruiting
- Sponsor
- Beijing Tiantan Hospital
- Start
- Feb 2024
- Primary completion
- Dec 2026
- Modality
- Whole Cell Cancer Vaccines, Dendritic Cell Vaccines
- Countries
- 1
01
Overview
Phase 1, open-label trial of ZSNeo-DC1.1 in glioma (2 arms), sponsored by Beijing Tiantan Hospital. Primary endpoints: Adverse Events and Serious Adverse Events at 2 years and Dose-Limiting Toxicity at 2 months. Started Feb 2024; status: active, not recruiting.
02
Drugs
ZSNeo-DC1.1
03
Conditions
glioma
Beyond the preview
Go deeper on NCT06253234.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06253234.